

Melanoma Advisory Committee Interests Register

Publication Date: 6th July 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Andrew Molyneux	Guideline Chair	Nil	N/A	N/A	N/A	N/A	N/A
Guy Burkhill	Radiologist	Direct, Financial	Private reporting of oncological PET-CT scans for NHS facility. Scans are not specifically skin cases.	2017	March 2020	Ongoing	Declare and participate Rationale: Activity is generic and not specific to skin cancer Approved by SS
Guy Burkhill	Radiologist	Direct, Financial	Reporting PET-CT scans for Alliance Medical under NHS National contract. Scans are allocated randomly by Alliance Medical and include occasional Melanoma cases.	2015	March 2020	Ongoing	Declare and participate Rationale: Member has no control over the allocation of work which is largely not specific to skin cancer Approved by SS
Guy Burkhill	Radiologist	Indirect, Non-financial, professional and personal	Member of a Sarcoma Trial working group examining different intensity imaging regimes in Sarcoma Surveillance. I have been asked to advise on how to	Sept 2021	Sept 2021	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic

			define disease relapse on imaging. The trial is still in the planning phase. No payment is received for this work.				Approved by SS
Guy Burkhill	Radiologist	Direct, Financial	Provision of consultancy services for Rinnova (https://www.rinnova.co.uk/) I will be providing advice to Rinnova on research they are conducting into variations in practice in England in the utilization of PET-CT scanning. My advice will be remunerated.	9th November 2021	November 2021	Ongoing	Declare and participate Rationale: Guideline does not recommend PET-CT. Approved by CM
William Bolland	GP	Direct, Financial	Partner at Affinity Care – group practice – Shipley Yorkshire.	April 2018	November 2019	Ongoing	Declare and participate Rationale: Practice does not run clinics specific to skin cancer. Approved by SS
William Bolland	GP	Direct, Financial	Partners at Affinity Care have received funding from industry that is paid into the partnership – Funding has been variously provided for attendance at meetings by: Abbot, Bayer, Boehringer-Ingelheim, Bristol Myers	April 2018	November 2019	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS

			<p>Squibb, Dawn, INRStar, Medtronic, Oberoi Consulting, Pfizer, Roche, SanofiAventis, Servier</p> <p>Practice partner has a funding grant from Health Foundation Fund for Innovation which includes working in partnership Oberoi Consulting. Practice partner has a grant from Health Education England to support development of genetics education for primary care.</p>				
William Bolland	GP	Direct, Financial	<p>Work in a community dermatology clinic providing general dermatology and skin lesion services including minor surgery. The service is provided by Westcliffe health innovations with payment through Affinity Care.</p>	Tbc	November 2019	Ongoing	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic.</p> <p>Approved by SS</p>
William Bolland	GP	Indirect, Financial	<p>A number of the partners at Affinity Care are board members and shareholders at Westcliffe Health Innovations.</p>	Tbc	November 2019	Ongoing	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p> <p>Approved by SS</p>

William Bolland	GP	Indirect, Financial	Family member is a consultant in old age psychiatry, working for Leeds and York Partnership NHS Foundation Trust and conducts research (both within the NHS and in collaboration with pharmaceutical companies) in the field of dementia and mental health.	Tbc	November 2019	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
William Bolland	GP	Indirect, Non-financial, professional and personal	<ul style="list-style-type: none"> • Colleagues at Affinity Care have the following interests: • -GP Advisor to the Yorkshire and Humber • -Dementia Strategic Clinical Network, • -Clinical Lead Bradford Research Clusters 1&2 • -GP on Y&H CRN Primary Care Steering Group • -Clinical Lead Bradford& Airedale Research group (BARG) with BDCFT-undertaking commercial research 	April 2018	November 2019	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS

			<ul style="list-style-type: none"> • -Member of Older People's Mental Health Expert Advisory Group • -Honorary Visiting Senior Research Fellow Bradford University School of Dementia Studies • -Co-applicant PROSPER research trial. • -Member of the ASPIRE Steering group • -Member of the LoTS-2-CARE steering group • -Member of the AURAS-AF steering group prescribing • -Medical Advisor to AF Association • -Medical Advisor to STARS (The syncope trust) • -Medical Advisor to National Stroke Association • -Medical Advisor to Anticoagulation Europe 				
--	--	--	---	--	--	--	--

			<ul style="list-style-type: none"> • -Trustee LifeBlood-the thrombosis charity • -Executive of the Arrhythmia Alliance • -Faculty member Heart Valve Voice • -Living Longer Lives Clinical Champion for NHS-IQ • -Medical Advisor to Yorkshire & Humber AHSN for AF NIC • -Council Member of the Yorkshire & Humber Clinical Senate • -Standing member of NICE Quality Standards committee. • -Director, West Yorkshire Medical Services (WYMS) Ltd – locum and resuscitation training agency. In the process of being wound up. • -Director – Quality Training Partnership. Currently not trading. WYMS Ltd has provided 				
--	--	--	--	--	--	--	--

			<p>locum services and resuscitation training to GP Practices within the CCG.</p> <ul style="list-style-type: none"> • -GP clinical associate to NHSE sustainable improvement team. • -LMC Representative for Bradford and Airedale District • -CoR planning group Chair – Bradford Districts CCG. • -Director/Vice Chair of YORLMC (North Yorkshire and Airedale and Bradford LMCs). • -National lead for Primary Care genomics education at HEE. 				
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Sanofi – Advisory Board. Working on non-melanoma MDT pathways and how to improve MDT process	2 nd December 2019	March 2020	2 nd December 2019	<p>Declare and participate</p> <p>Rationale:</p> <p>Interest specific to scope of update but occurred prior to appointment and has now ceased. No ongoing relationship with funder.</p>

							Approved by SS
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Attended Pierre-Fabre funded educational conference – 9 th European post Chicago melanoma/skin cancer meeting	20 th June 2019	March 2020	21 st June 2019	<p>Declare and participate</p> <p>Rationale:</p> <p>Interest specific to scope of update but occurred prior to appointment and has now ceased. No ongoing relationship with funder.</p> <p>Approved by SS</p>
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Speaker at Janssen funded educational event – prescribing workshop for non-medical prescribers	28 th June 2019	March 2020	28 th June 2019	<p>Declare and participate</p> <p>Rationale: Interest not specific to scope of guideline update and has now ceased. No ongoing relationship with funder.</p> <p>Approved by SS</p>
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Speaker at Bristol Myers-Squibb funded educational event – non-medical prescribing presentation: how to set up a new NHS clinic	5 th June 2019	March 2020	5 th June 2019	<p>Declare and participate</p> <p>Rationale: Interest not specific to scope of guideline update and has now ceased. No ongoing relationship with funder.</p>

							Approved by SS
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Speaker at Novartis funded educational event - non-medical prescribing presentation: how to set up a new NHS clinic	3 rd April 2019	March 2020	3 rd April 2019	<p>Declare and participate</p> <p>Rationale: Interest not specific to scope of guideline update and has now ceased. No ongoing relationship with funder.</p> <p>Approved by SS</p>
Dharmisha Chauhan	Co-opted Pharmacist	Non-financial, professional and personal	British Oncology Pharmacy Association – treasurer on the executive committee. Non-paid position	13 th October 2019	March 2020	Ongoing	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p> <p>Approved by SS</p>
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Sanofi – Presentation on quality of life and toxicity management for cemiplimab for non-melanoma skin cancer (cutaneous squamous cell carcinoma)	May 2021	28 th April 2021	28 th April 2021	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p> <p>Approved by SS</p>
Susan Cheetham	Lay Member	Non-financial, professional and personal	Assist the charity SKCIN alongside the Macmillan Nurse in raising awareness in schools and colleges in	2017	March 2020	Ongoing	<p>Declare and participate</p>

			respect of skin care in the sun				Rationale: Not specific to any particular guideline topic Approved by SS
Fiona Collier	GP	Non-financial, professional and personal	GP Advisor to Hidradenitis Suppurativa Trust (charity) This is a nominal voluntary post, advising the charity on any medical matter relevant to hidradenitis suppurativa, a chronic skin disease.	2016	July 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Fiona Collier	GP	Non-financial, professional and personal	Principal Investigator for NHS Forth Valley for THESEUS, a NIHR-funded observational trial into current treatment of Hidradenitis Suppurativa, a chronic inflammatory skin condition. No direct relation to skin cancer, but is research on a dermatological topic.	2019	July 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Fiona Collier	GP	Indirect, Financial	Husband employed by Siemens UK (who manufacture CT and MRI machines) as a national technical support engineer. No shares owned.	N/A	September 2020	Ongoing	Declare and participate Rationale: Guideline will not make recommendations on purchasing of equipment

							and no shares in company are owned. Approved by SS
Gillian Godsell	Nurse	Nil	N/A	N/A	N/A	N/A	N/A
Sarah Hemington-Gorse	Plastic Surgeon	Nil	N/A	N/A	N/A	N/A	N/A
Ian James	Lay Member	Non-financial, professional and personal	Member of Melanoma Patient Network Europe – A European patient network that educates and advocate for research and access in Melanoma across Europe	2015	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Ian James	Lay Member	Non-financial, professional and personal	Member and administrator of ‘melanomamates’ - patient support group hosted on Facebook	2013	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Ian James	Lay Member	Non-financial, professional and personal	Speaker at Melanoma Patient Conference UK – no payment	20 th June 2019	March 2020	20 th June 2019	Declare and participate Rationale: Not specific to any particular guideline topic

							Approved by SS
Lynne Jamieson	Histopathologist	Direct, Financial	Private Practice - histopathology reporting of cases for Spire Healthcare based at Spire Manchester Pathology. Reporting only on Dermatopathology (skin biopsy samples) and mirrors NHS practice. Constitutes approx. 5% of overall workload.	2007	March 2020	Ongoing	<p>Declare and participate</p> <p>Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully</p> <p>Approved by SS</p>
Lynne Jamieson	Histopathologist	Direct, Financial	Private Practice - histopathology reporting of outsourced cases from various healthcare organisations for Source Bioscience. Work mirrors NHS practice and constitutes 5 to 10% of overall workload.	2019	March 2020	Ongoing	<p>Declare and participate</p> <p>Rationale: As above</p> <p>Approved by SS</p>
Lynne Jamieson	Histopathologist	Direct, Financial	Private Practice – histopathology reporting of	2007	March 2020	Ongoing	Declare and participate

			cases sent via private clinics at Salford Royal Hospital. Work mirrors NHS practice and volume of work is very low.				Rationale: as above Approved by SS
Lynne Jamieson	Histopathologist	Non-financial professional and personal	Chair of the Specialty Advisory Committee for Dermatopathology for the Royal College of Pathologists advising the Royal College on matters arising in Dermatopathology. Subspecialty advisor providing stakeholder comment where necessary on National Guidelines drawn up by partner organisations which pertain to dermatopathology including NICE documents.	2016	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Lynne Jamieson	Histopathologist	Non-financial professional and personal	Chair of a sub- committee for Greater Manchester Cancer Skin pathway board on MDT reform. Document drafted on MDT reform in GM but not published yet..	2018	March 2020	Ongoing	Declare and participate Rationale: Participation reviewed if MDT reform is discussed Approved by SS

Stephen Keohane	Dermatologist	Direct, Financial	Private Dermatology Practice which takes up 10% of overall work (90% work in NHS practice). Payment received per intervention and consultation. Practice mirrors NHS practice.	November 2019	November 2020	Ongoing	<p>Declare and participate</p> <p>Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully</p> <p>Approved by SS</p>
Stephen Keohane	Dermatologist	Direct, Financial	Roche Posay speaker meeting, not specific to guideline scope, honorarium received.	24 th March 2019	November 2020	24 th March 2019	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p> <p>Approved by SS</p>
Stephen Keohane	Dermatologist	Non-financial professional and personal	President British Society of Dermatological Surgery	1 st July 2019	November 2020	Ongoing	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p>

							Approved by SS
Stephen Keohane	Dermatologist	Non-financial professional and personal	Chair Multi-professional guidelines committee for cutaneous Squamous Cell Carcinoma, administered by the British Association of Dermatologists.	1 st July 2016	November 2020	Ongoing	Declare and participate Rationale: Participation reviewed if cutaneous Squamous Cell Carcinoma reform is discussed Approved by SS
Stephen Keohane	Dermatologist	Non-financial professional and personal	Skin Cancer lead NHS E Specialised commissioning CRG for Dermatology	1 st August 2019	November 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Stephen Keohane	Dermatologist	Direct, Financial	Sanofi – Presentation on quality of life and toxicity management for cemiplimab for non-melanoma skin cancer (cutaneous squamous cell carcinoma)	May 2021	28 th April 2021	28 th April 2021	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
John Lear	Dermatologist	Direct, Financial	Private practice in general dermatology 1-2 sessions a week, NHS contract is 7 pa's per week.	2000	March 2020	Ongoing	Declare and participate Rationale: Private practice in this area is a small proportion of the

							individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully Approved by SS
John Lear	Dermatologist	Direct, Financial	Mayne Pharma, LEO, Sanofi, Consultancy, Speaker fees for product in BCC/SCC and Gorlin syndrome, not melanoma	2018	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Christine Parkinson	Medical Oncologist	Non-financial professional and personal	CA209-192 phase III trial of nivolumab funded by BMS. Principle investigator for the study in Cambridge.	18 th February 2015	March 2020	31 st December 2019	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Christine Parkinson	Medical Oncologist	Non-financial professional and personal	PI for Keynote 775 phase III for metastatic endometrial cancer using –	17 th October 2018	March 2020	Ongoing	Declare and participate

			pembrolizumab + lenvatinib funded by Merck.				Rationale: Not specific to any particular guideline topic Approved by SS
Christine Parkinson	Medical Oncologist	Non-financial professional and personal	PI for ATHENA – phase III trial of maintenance treatment in ovarian cancer. Placebo controlled nivo/placebo v rucaparib/placebo, funded by CLOVIS.	27 th March 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Christine Parkinson	Medical Oncologist	Non-financial professional and personal	Local principle investigator for a melanoma trial 'CACTUS', an academic trial - no payment received. The trial randomizes BRAF mutant patient to investigator choice of first line treatment v dab+tram.	November 2021	November 2021	Ongoing	Declare and participate Rationale: non-paid academic involvement which does not impact guideline. Approved by CM
Howard Peach	Plastic Surgeon	Direct, Financial	Private practice through 'Peach Skin Clinic Ltd.' (sole Director) – Private practice constitutes 5% of workload (95% in NHS). Scope of private work reflects NHS practice. Charge is made per appointment /procedure.	2006	March 2020	Ongoing	Declare and participate Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a

							view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully Approved by SS
Howard Peach	Plastic Surgeon	Direct, Financial	Scientific advisory board – AMGEN	18 th October 2019	March 2020	18 th October 2019	Declare and participate Rationale: Interest specific to scope of update but occurred prior to appointment and has now ceased. No ongoing relationship with funder Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Trustee for charity 'Melanoma Focus'	2014	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Scientific committee member 'Melanoma Focus'	2014	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic

							Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	WYork & Harrogate Cancer Alliance representative	1 st May 2020	March 2020	01/05/2020	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p> <p>Approved by SS</p>
Howard Peach	Plastic Surgeon	Non-financial professional and personal	PI - Minitub registration study, funded by the European Organisation for Research and Treatment of Cancer.	Aug 2012	March 2020	Ongoing	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p> <p>Approved by SS</p>
Howard Peach	Plastic Surgeon	Non-financial professional and personal	PI - MelMarT melanoma excision margins trial - Pilot No funding in UK, overarching funding from Cancer Council New South Wales (CCNSW), Australia	July 2014	March 2020	Completed	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p> <p>Approved by SS</p>
Howard Peach	Plastic Surgeon	Non-financial professional and personal	PI - MelMarT melanoma excision margins trial – Main-Funding still being decided. Main Sponsor from CCNSW	TBC	March 2020	Ongoing	<p>Declare and participate</p> <p>Rationale: Not specific to any particular guideline topic</p>

							Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Main author on current BAPRAS/BAD UK guidelines on melanoma	2010	March 2020		Declare and participate Rationale: Participation reviewed if BAD UK guidelines are discussed Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Advisor to NICE on Interventional Procedures for skin cancer	2012	March 2020	2015	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Chaired a multi-disciplinary meeting organised by Melanoma Focus – following which a UK Consensus statement on SNBx for cutaneous melanoma was published	Jan 2020	March 2020	Jan 2020	Declare and participate Rationale: Participation reviewed if SNBx for cutaneous melanoma is discussed Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Author on Ano-Uro-Genital Mucosal Melanoma guidelines published by Melanoma Focus	May 2018	March 2020	May 2018	Declare and participate Rationale: Participation reviewed if Ano-Uro-

							Genital Mucosal Melanoma guidelines are discussed Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	<p>Several papers, presentations and posters relating to melanoma management:</p> <p>A Mitra, S. E., J Smith, H Peach, M Marples & J Newton-Bishop (2010). "A case of epidermotropic metastatic melanoma simulating multiple primary melanomas."</p> <p>Peach AH et al (2019). "BAD Melanoma patient information leaflets."</p> <p>Alyss V Robinson¹, C. K., Owen Thornton², Howard Peach⁴, Maria Marples^{1,3}, Donald J Dewar⁴, Ryckie G Wade^{1,4} (2017). "NLR and PLR as biomarkers for surveillance in cutaneous melanoma."Poster.</p> <p>Bevin Bhojrul, G. B., Faye Elliott, Joanna McLorinan, Amy Wilson, Howard Peach, Bipin Mathew, Angana Mitra (2019). "Pathological review of primary cutaneous malignant melanoma by a specialist skin cancer multidisciplinary team improves</p>	2007-2020	March 2020	Ongoing	<p>Declare and participate</p> <p>Rationale: Participation will be reviewed in the event of any publications included in the evidence base.</p> <p>Approved by SS</p>

			<p>patient care in the UK." J Clin Pathology: 5.</p> <p>Bramhall R.J., M. K. F., Peach A.H.S. (2009). "Spontaneous Regression of Metastatic Melanoma." Poster.</p> <p>Carbone A, W. R., Peach H (2017). "A safe way to reduce the length of hospital stay following lymph node dissection for skin malignancy: The Leeds Experience." Presentation – BAPRAS Finland.</p> <p>F Al-Hassani, C. C., H.Peach (2017). "Acral Lentiginous melanoma - Is inflammation the missing link?" JPRAS Open 14: 6.</p> <p>J.R. Marsden, J. A. N.-B., * L. Burrows, M. Cook,à P.G. Corrie,§ N.H. Cox,— M.E. Gore,** P. Lorigan, R. MacKie,àà P. Nathan,§§ H. Peach,— B. Powell*** and C. Walker (2010). "Revised U.K.guidelines for the management of cutaneous melanoma 2010." British Journal of Dermatology 163: 18.</p> <p>Lo MCI, R. A., Wade RG, Peach H, Dewar DJ, Heaton MJ, Moncrieff MDS (2018). "The Prognostic Significance of</p>				
--	--	--	--	--	--	--	--

			<p>Extracapsular Spread (ECS) in Sentinel Node Positive (SLN+) Patients for Cutaneous Melanoma." Society of Surgical Oncology Annual Symposium(Chicago, USA).</p> <p>Macdonald, C. G., J.2 ; Brackley, P.2 ; Cassell, O.3 ; Geh, J.4 ; Odili, J.5 ; Peach, H.6 ; Thompson, J.7 ; Wallace, D.8 ; Moncrieff, M. (2013). "The Impact on Quality of Life and Reconstructive Need of Wider Excision Margins >1 cm for Primary Cutaneous Melanoma." Journal der Deutschen Dermatologischen Gesellschaft 11(Suppl 7.): 1.</p> <p>Mitra A, C. C., Walker C, Cook M, Powell B, Lobo S, Chan M, Kissin M, Layer G, Smallwood J, Ottensmeier C, Stanley P, Peach H, Chong H, Elliott F, Iles MM, Nsengimana J, Barrett JH, Bishop DT, Newton-Bishop JA. (2010). "Melanoma sentinel node biopsy and prediction models for relapse and overall survival." British Journal of Cancer Oct(130(8)).</p> <p>Moncrieff, M. D., et al. (2018). "1 Versus 2-cm Excision Margins for pT2-pT4 Primary</p>				
--	--	--	--	--	--	--	--

			<p>CutaneousMelanoma (MeIMarT): A Feasibility Study." Annals of Surgical Oncology 25(9): 2541-2549.</p> <p>Peach AH, M. M., Pritchard-Jones R (2020). "Advice for managing Melanoma patients during Coronavirus pandemic." BAPRAS March.</p> <p>Peach, H. S., et al. (2013). "The unpredictability of lymphatic drainage from the ear in melanoma patients, and its implications for management." Ann Surg Oncol 20(5): 1707-1713.</p> <p>RM Pinder, M. S., F Elliott, A Boon, C Topham, AHS Peach (2010). "Histopathological predictors of survival in node dissections in metastatic melanoma."</p> <p>Robinson A, K. C., Peach H, Dewar D, Marples M, Wade R (2017). "Baseline neutrophillymphocyte,platelet-lymphocyte and lymphocyte-monocyte ratios did no predict survival in cutaneous malignant melanoma." Canadian Journal of Surgery 60(4).</p>				
--	--	--	--	--	--	--	--

			<p>Robinson AV, K. C., Peach H, Marples M, Dewar D, Wade RG (2017). "Baseline neutrophillymphocyte ratio is associated with metastases of cutaneous melanoma to the sentinel lymphnode." Journal of the European Academy of Dermatology and Venereology 31(46).</p> <p>Robinson AV, K. C., Peach H, Marples M, Dewar D, Wade RG (2017). "Baseline neutrophillymphocyte,platelet-lymphocyte and lymphocytemonocyte ratios predict survival in cutaneous malignant melanoma." Journal of the European Academy of Dermatology and Venereology 31(57).</p> <p>Robinson, A. V., et al. (2020). "The neutrophil–lymphocyte ratio and locoregional melanoma: amulticentre cohort study." Cancer Immunology, Immunotherapy.</p> <p>Robinson AV, P. H., Wade RG (2018). "ASO Author Reflections: Haematological biomarkers in cutaneous melanoma." Annals of Surgical Oncology 25(s3): 2.</p>				
--	--	--	--	--	--	--	--

			<p>S.M. Field, J. D., A Mitra, H., Peach, D. Dewar, J.A. Newton-Bisho (2013). "A Clinical Audit of theEffect of Targeted Advice and Vitamin D Supplementation on Serum Vitamin D Levels in Patientswith Melanoma."</p> <p>Smith, H., et al. (2020). "Ano-uro-genital mucosal melanoma UK national guidelines." European Journal of Cancer 135: 22-30.</p> <p>Smith, H., Bagwan I, Board R, Peach H (2020). "Ano-uro-genital mucosal melanoma UK national guidelines." European Journal of Cancer 135: 9.</p> <p>Smith, H., et al. (2020). "Less Is More – A Systematic Review of the Outcomes of Radical Versus Conservative Primary Resection in Anorectal Melanoma." European Journal of Surgical Oncology 46(2): e13-e13.</p> <p>Thomson CH, C. O., Peach H, Holloway S, Garioch J, Moncrieff M (2017). "Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: amulticentre study." Melanoma Research 27: 5.</p>				
--	--	--	---	--	--	--	--

			<p>Wade, R. G., et al. (2018). "Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study." <i>Annals of Surgical Oncology</i> 25(11): 3341-3349.</p> <p>West CA., S. D., Peach H. (2014). "Combined clearance of Pelvic and superficial nodes for clinical groin melanoma." <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> 67(12): 8.</p>				
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Advisory Board, MSD – discussing managing high risk stage II and all stage III/IV patients with systemic therapy	Oct 2021	Oct 2021	Jan 2022	<p>Declare and participate</p> <p>Rationale: Interest not specific to scope of guideline update. No ongoing relationship with funder</p> <p>Approved by CM</p>
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Advisory Board, Almirall, Psoriasis Biologic - honorarium payment	19th March 2019	March 2020	19th March 2019	<p>Declare and participate</p> <p>Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and</p>

							has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	CNS Meeting on psoriasis Janssen – speakers fee received.	16th June 2019	March 2020	16th June 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	British Dermatological Nursing Group 2019, Harrogate – sponsor Lilly funded- travel, accommodation and attendance costs.	25th June 2019	March 2020	27th June 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Workshop facilitation for psoriasis/ dermatology nurses, Novartis – payment received	23rd November 2019	March 2020	23rd November 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and

							has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Webinar / psoriasis– Janssen- payment received	16th September, 21st & 27th of November, 3rd December 2019	March 2020	3rd December 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Janssen-Cilag Limited, EADV 2019- travel, accommodation and attendance costs	9 th October 2019	March 2020	13th October 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Meeting Novartis- psoriasis – payment received.	30 th January 2020	March 2020	30 th January 2020	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and

							has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Non-financial professional and personal	Teaching on MSc Dermoscopy module , University Hertfordshire – unpaid Once to twice yearly	May 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Non-financial professional and personal	Physical Examination Day for Skin Cancer CNS's, University of Hertfordshire - unpaid	4 th July 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Non-financial professional and personal	Organising Annual Conference British Association Skin Cancer Nurse Specialists	November 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Non-financial professional and personal	Organising national skin cancer study days for British Dermatological Nursing Group	November 2019	March 2020	Ongoing	Declare and participate

							Rationale: Not specific to any particular guideline topic Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Attended the BAD Virtual Conference by Eli Lilly – registration fee received.	September 2020	September 2020	N/A	Declare and participate Rationale: Interest not specific to scope of guideline update. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Attended British Association of Dermatologists (BAD) conference – registration fee covered by UCB Pharma.	July 2021	Aug 2021	July 2021	Declare and participate Rationale: Interest not specific to scope of guideline update. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Attended British Dermatological Nursing Group conference – registration fee covered by AbbVie.	Sept 2021	Aug 2021	Sept 2021	Declare and participate Rationale: Interest not specific to scope of guideline update. No

							ongoing relationship with funder Approved by SS
Myles Smith	General Surgeon	Direct, Financial	Advisory Board, Amgen (T-VEC therapy). One off payment received.	18 th October 2019	March 2020	18 th October 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Myles Smith	General Surgeon	Direct, Financial	Partner, HCA Joint Venture, Chiswick Medical Centre LLP(https://www.hcahealthcare.co.uk/facilities/the-harley-street-clinic/centres-and-teams/chiswick-medical-centre) 0.4% Shareholding. Chiswick is a diagnostic centre, providing standard medical care. Clinic is a general clinic that reflects NHS scope of practice.	27 th November 2017	March 2020	Ongoing	Declare and participate Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.

							Approved by SS
Myles Smith	General Surgeon	Direct, Financial	Private practice which mirrors NHS scope of practice, 10%.90% of work NHS - 11Pa's NHS.	February 2017	March 2020	Ongoing	Declare and participate Rationale: As above Approved by SS
Myles Smith	General Surgeon	Non-financial professional and personal	RCS Surgical Tutor at RMH.	October 2016	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Myles Smith	General Surgeon	Non-financial professional and personal	1: Smith HG, Glen J, Turnbull N, Peach H, Board R, Payne M, Gore M, Nugent K, Smith MJF. Less is more: A systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanoma. Eur J Cancer. 2020 Aug;135:113-120. doi: 10.1016/j.ejca.2020.04.041. Epub 2020 Jun 18. PMID: 32563895. 2: Snow H, Hazell S, Francis N, Mohammed K,	2007-2020	September 2020	N/A	Declare and participate Rationale: Participation will be reviewed in the event of any publications included in the evidence base. Approved by SS

			<p>O'Neill S, Davies E, Mansfield D, Messiou C, Hujairi N, Nicol D, Harrington K, Smith M. Prostate-specific membrane antigen expression in melanoma metastases. J Cutan Pathol. 2020 Jun 11. doi: 10.1111/cup.13774. Epub ahead of print. PMID: 32529651.</p> <p>3: Smith HG, Bagwan I, Board RE, Capper S, Coupland SE, Glen J, Lalondrelle S, Mayberry A, Muneer A, Nugent K, Pathiraja P, Payne M, Peach H, Smith J, Westwell S, Wilson E, Rodwell S, Gore M, Turnbull N, Smith MJF. Ano-uro-genital mucosal melanoma UK national guidelines. Eur J Cancer. 2020 Aug;135:22-30. doi: 10.1016/j.ejca.2020.04.030. Epub 2020 Jun 9. PMID: 32531566.</p> <p>4: Smith MJF, Smith HG, Joshi K, Gore M, Strauss DC, Hayes AJ, Larkin J. The impact of effective</p>				
--	--	--	---	--	--	--	--

			<p>systemic therapies on surgery for stage IV melanoma. Eur J Cancer. 2018 Nov;103:24-31. doi: 10.1016/j.ejca.2018.08.008. Epub 2018 Sep 7. PMID: 30196107.</p> <p>5: Snow HA, Hofman MS, Mitchell CA, Gyorki DE, Smith MJF. Incidental Metastatic Melanoma Identified on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer. Clin Nucl Med. 2018 Jul;43(7):509-511. doi: 10.1097/RLU.00000000000002111. PMID: 29742609.</p> <p>6: Smith HG, Wilkinson MJ, Smith MJF, Strauss DC, Hayes AJ. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies. Eur J Cancer. 2018 Sep;100:46-54. doi: 10.1016/j.ejca.2018.04.014. Epub 2018 Jun 22. PMID: 29940423.</p>				
--	--	--	--	--	--	--	--

			<p>7: Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendeus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22. PMID: 29576375; PMCID: PMC5904288.</p> <p>8: Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D,</p>				
--	--	--	--	--	--	--	--

			<p>Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA. Fc-Optimized Anti-CD25 Depletes Tumor- Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11. PMID: 28410988; PMCID: PMC5437702.</p> <p>9: Moran DE, Smith MJ, O'Sullivan MJ, Bannon H, Crotty TB, Collins CD, Skehan SJ, O'Higgins N, McDermott EW, Evoy D, Hill AD. Sentinel lymph node biopsy in elderly irish patients with malignant</p>				
--	--	--	--	--	--	--	--

			melanoma. Ir Med J. 2007 Apr;100(4):422-4. PMID: 17566474.				
Myles Smith	General Surgeon	Indirect, Financial	Updated the melanoma text on melanoma online, and recently ECT for Cancer research UK. Reimbursement fund was directed to the Sarcoma and Melanoma Research Fund.	2020	September 2020	N/A	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS
Myles Smith	General Surgeon	Non-financial professional and personal	Updated Macmillan online text with regards to Anorectal melanoma.	2020	September 2020	N/A	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS
Myles Smith	General Surgeon	Direct, Financial	BRC Research Fellow Grant for Preoperative Planning PSMA-PET in Melanoma Surgery (PPPIMS). Fellowship planned to start in October 2021.	9 th April 2021	Sept 2021	Will cease 31 st March 2022	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS
Myles Smith	General Surgeon	Direct, Financial	BRC pump priming grant to be received for the project: Preoperative Planning PSMA-PET in Melanoma	March 2021	Sept 2021	Will cease 31 st March 2022	Declare and participate Rationale: Not specific to any particular guideline topic.

			Surgery (PPPIMS). Project reference: B130. Funds not yet transferred yet as the project and fellowship have not started.				Approved by SS
Myles Smith	General Surgeon	Direct, Financial	Attendance at iSPIES conference in Amsterdam, a Stryker event, related to fluorescence guided surgery (FSG). Travel, attendance and accommodation paid for by Stryker.	18 th October 2021	November 2021	19 th October 2021	Declare and participate Rational: Interest does not overlap with scope of update. Approved by CM
Delia Sworm	Oncology Nurse Specialist	Nil	N/A	N/A	N/A	N/A	N/A
Steve Watkins	Oncologist	Direct, Financial	Member of advisory board for content of educational event regarding Cutaneous Squamous Cell Cancers and Cemipilimab immunotherapy for Sanofi GENZTME pharmaceutical.	May 2019	November 2019	11 th November 2019	Declare and participate Rationale: Interest specific to scope of update but occurred prior to appointment and has now ceased. No ongoing relationship with funder. Approved by SS
Steve Watkins	Oncologist	Direct, Financial	Member of advisory board looking at Cutaneous Squamous Cell Cancer treatment pathways and	September 2019	November 2019	2 nd December 2019	Declare and participate Rationale: Interest specific to scope of update but

			Cemipilimab immunotherapy within them for Sanofi GENZTME pharmaceutical.				occurred prior to appointment and has now ceased. No ongoing relationship with funder. Approved by SS
Sophie Wilne	Co-opted Paediatric Oncologist	Nil	N/A	N/A	N/A	N/A	N/A
Steven Connor	Consultant radiologist – Expert witness	Indirect, Financial	Private practice (<0.5% of work pertaining to melanoma)	2002	May 2021	Ongoing	Declare and participate Rational: Approved by SS

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.